CN114606236B - 一种翘芪复方中药汤剂来源的微小核糖核酸及其制备方法和应用 - Google Patents
一种翘芪复方中药汤剂来源的微小核糖核酸及其制备方法和应用 Download PDFInfo
- Publication number
- CN114606236B CN114606236B CN202210424718.8A CN202210424718A CN114606236B CN 114606236 B CN114606236 B CN 114606236B CN 202210424718 A CN202210424718 A CN 202210424718A CN 114606236 B CN114606236 B CN 114606236B
- Authority
- CN
- China
- Prior art keywords
- ribonucleic acid
- micro ribonucleic
- chinese medicinal
- influenza
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920002477 rna polymer Polymers 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 239000009636 Huang Qi Substances 0.000 title description 4
- 239000003814 drug Substances 0.000 claims abstract description 25
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 239000002773 nucleotide Substances 0.000 claims abstract description 19
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 19
- 206010022000 influenza Diseases 0.000 claims abstract description 16
- 230000003612 virological effect Effects 0.000 claims abstract description 14
- 241001678559 COVID-19 virus Species 0.000 claims description 9
- 241001473385 H5N1 subtype Species 0.000 claims description 9
- 208000002979 Influenza in Birds Diseases 0.000 claims description 4
- 206010064097 avian influenza Diseases 0.000 claims description 4
- 206010035737 Pneumonia viral Diseases 0.000 claims description 3
- 208000009421 viral pneumonia Diseases 0.000 claims description 3
- 208000037798 influenza B Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 16
- 108091070501 miRNA Proteins 0.000 abstract description 15
- 239000002679 microRNA Substances 0.000 abstract description 15
- 206010035664 Pneumonia Diseases 0.000 abstract description 12
- 241001061264 Astragalus Species 0.000 abstract description 8
- 241000196324 Embryophyta Species 0.000 abstract description 8
- 235000006533 astragalus Nutrition 0.000 abstract description 8
- 210000004233 talus Anatomy 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract description 3
- 239000000284 extract Substances 0.000 abstract description 3
- 239000002243 precursor Substances 0.000 abstract description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 28
- 241000712461 unidentified influenza virus Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 108700011259 MicroRNAs Proteins 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000029812 viral genome replication Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000713196 Influenza B virus Species 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 108091030909 Brachypodium distachyon miR159 stem-loop Proteins 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108091087422 Physcomitrella patens miR894 stem-loop Proteins 0.000 description 2
- 108091055956 Picea abies miR3711 stem-loop Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 240000004510 Agastache rugosa Species 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 235000001405 Artemisia annua Nutrition 0.000 description 1
- 240000000011 Artemisia annua Species 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 241001463143 Auca Species 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 241000576429 Forsythia suspensa Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000012898 Olfaction disease Diseases 0.000 description 1
- 240000002948 Ophiopogon intermedius Species 0.000 description 1
- 206010034018 Parosmia Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241001180876 Saposhnikovia Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
Abstract
本发明公开了一种翘芪复方中药汤剂来源的微小核糖核酸及其制备方法和应用,所述微小核糖核酸选自核苷酸序列如SEQ ID NO.1~15所示的miRNA,优选为QQ_159,包括人工合成的QQ_159、植物QQ_159、QQ_159的前体形式或QQ_159的成熟体形式;所述QQ_159的核苷酸序列如SEQ ID NO.14所示。本发明从翘芪复方中药汤剂中提取功能性植物微小核糖核酸或含该微小核糖核酸提取物,并通过实验验证了该翘芪复方中药汤剂来源的微小核糖核酸QQ_159对病毒性流行性感冒及新型冠状病毒感染导致的肺炎存在一定的抑制效果和治疗作用。
Description
技术领域
本发明属于生物医药技术领域,具体涉及一种翘芪复方中药汤剂来源的微小核糖核酸及其制备方法和应用。
背景技术
流行性感冒(简称流感)是哺乳动物和家禽常患的一种急性呼吸道疾病,由流感病毒引起,传染性强、传播速度快,通常会导致简单的呼吸道感染,包括咳嗽、发烧、肌痛、发冷或出汗等临床症状,不适感可持续2至8天,通常发病迅速。部分患者,尤其是老年人、幼儿和患有其他慢性疾病的患者,易引发病毒性或继发性肺炎,甚至伴有呼吸困难和多器官衰竭。使用抗流感药物治疗是目前对抗流感的一种常用手段,一般根据患者的感染程度及患者身体状况来决定处方。虽然流感病毒是研究最深入的病原体之一,但由于流感病毒极易变异,现有的控制及治疗方案还需要不断改进,研发针对病毒性流行性感冒的新药既是当今社会的重大需求,也是民生健康的重大需求。
新型冠状病毒(简称新冠)是最近两年广泛传播的一种新型病毒,主要通过飞沫形式的呼吸途径传播,近来还发现可通过气溶胶、物品接触传播,传染性极强,传播速度极快,临床症状主要表现为:发热、疲劳、干咳、嗅觉缺失/嗅觉障碍,严重者或伴有呼吸困难、呼吸急促和低氧血症的严重肺炎并可引发其他并发症。因目前没有针对新冠病毒的特效治疗药物,导致其在全球大规模传播。因此,针对疫情防控的药品需求,研发特异性针对新冠的新药品是应对新冠、保障人民生命安全的重要手段。
微小核糖核酸(microRNAs,简称miRNAs)是一类小的内源性非编码RNA。通常情况下,miRNA编码基因由RNA聚合酶Ⅱ转录并产生初级转录物,由RNaseⅢ核酸内切酶Drosha和Dicer加工成大约21个核苷酸的小RNA。miRNA通过与编码区或靶mRNA的3’和5’非翻译区的结合,介导转录后基因沉默,在多种生理病理过程中发挥着重要作用,在医学领域具有广阔的应用前景。
近年来,植物miRNA相关研究发展迅速,主要通过上调/下调策略研究其生物学功能,众多研究表明其在光合作用、营养稳态、生长发育、激素信号转导以及胁迫响应等方面都发挥着重要的调控作用;此外,已证实植物miRNA可作为内源性miRNA调节动物基因表达。大量文献报道中药在预防和治疗流感及新冠肺炎过程中发挥了积极作用。但具体是哪种有效成分尚不明确。已有文献报道在中药中含有miRNA,但中药汤剂中存在哪些稳定存在的miRNA,这些miRNA进入动物体内会发挥什么样的功能,人们对其仍不甚了解。
发明内容
针对现有技术的不足,本发明提供一种翘芪复方中药汤剂来源的微小核糖核酸及其制备方法和应用,从翘芪复方中药汤剂中提取功能性植物微小核糖核酸或含该微小核糖核酸提取物,并通过实验验证了该翘芪复方中药汤剂来源的微小核糖核酸QQ_159对病毒性流行性感冒及新型冠状病毒感染导致的肺炎存在一定的抑制效果和治疗作用。
本发明是通过以下技术方案实现的:
一种翘芪复方中药汤剂来源的微小核糖核酸,所述微小核糖核酸选自novel_mir7、novel_mir33、novel_mir35、novel_mir10、novel_mir20、novel_mir5、novel_mir36、novel_mir28、novel_mir31、ppt-miR894、novel_mir32、novel_mir21、pab-miR3711、QQ_159或bdi-miR159a-3p;其中,
所述novel_mir7的核苷酸序列如SEQ ID NO.1所示;
所述novel_mir33的核苷酸序列如SEQ ID NO.2所示;
所述novel_mir35的核苷酸序列如SEQ ID NO.3所示;
所述novel_mir10的核苷酸序列如SEQ ID NO.4所示;
所述novel_mir20的核苷酸序列如SEQ ID NO.5所示;
所述novel_mir5的核苷酸序列如SEQ ID NO.6所示;
所述novel_mir36的核苷酸序列如SEQ ID NO.7所示;
所述novel_mir28的核苷酸序列如SEQ ID NO.8所示;
所述novel_mir31的核苷酸序列如SEQ ID NO.9所示;
所述ppt-miR894的核苷酸序列如SEQ ID NO.10所示;
所述novel_mir32的核苷酸序列如SEQ ID NO.11所示;
所述novel_mir21的核苷酸序列如SEQ ID NO.12所示;
所述pab-miR3711的核苷酸序列如SEQ ID NO.13所示;
所述QQ_159的核苷酸序列如SEQ ID NO.14所示;
所述bdi-miR159a-3p的核苷酸序列如SEQ ID NO.15所示。
优选地,所述微小核糖核酸为QQ_159,包括人工合成的QQ_159、植物QQ_159、QQ_159的前体形式或QQ_159的成熟体形式。
一种翘芪复方中药汤剂来源的微小核糖核酸的制备方法,包括以下步骤:
步骤1)将300mL翘芪复方中药汤剂分装于50mL除酶离心管中,2000rpm离心去除杂质;按每管10mL吸取上清置于冰上,按药汤体积3倍比例加入TRIzol ls 30mL,用力震荡均匀后,室温静置10min,然后加入6mL氯仿,用力震荡均匀,静置10min;
步骤2)离心10000g,4℃,10min,收集上清;
步骤3)加入等体积的异丙醇-20℃沉淀1h,然后离心12000g,15min;
步骤4)小心弃上清,加入5mL的75%的乙醇洗沉淀,4℃,12000g离心5min;
步骤5)离心后,小心弃去乙醇,留沉淀,待沉淀干燥后加200μL 65℃DEPC水溶解,测定RNA浓度;
步骤6)用商用miRNA isolation kit纯化miRNA,每个柱子过100μg RNA,每管用60μL DEPC水溶解;
步骤7)测定miRNA浓度,冷冻干燥8h后,-80℃保存。
一种翘芪复方中药汤剂来源的微小核糖核酸QQ_159在制备抑制流行性感冒病毒复制的药物中的应用。
一种翘芪复方中药汤剂来源的微小核糖核酸QQ_159在制备治疗病毒性流行性感冒的药物中的应用。
优选地,所述流行性感冒包括乙型victoria流行性感冒或H5N1禽流感。
一种翘芪复方中药汤剂来源的微小核糖核酸QQ_159在制备抑制SARS-CoV-2病毒复制的药物中的应用。
一种翘芪复方中药汤剂来源的微小核糖核酸QQ_159在制备治疗SARS-CoV-2病毒引起的病毒性肺炎的药物中的应用。
一种用于抑制流行性感冒病毒复制和/或治疗流行性感冒的药物组合物,包括上述的微小核糖核酸QQ_159,及其药学上可接受的载体。
一种用于抑制SARS-CoV-2病毒复制和/或治疗SARS-CoV-2病毒引起的病毒性肺炎的药物组合物,包括上述的微小核糖核酸QQ_159,及其药学上可接受的载体。
一种体外非治疗目的的抑制乙型victoria流感病毒复制的方法:将上述的微小核糖核酸QQ_159与被乙型victoria流感病毒感染的细胞进行接触。
本发明的有益效果如下:
本发明提供了一种提取中药汤剂中微小核糖核酸的实验方法,并首次用此法提取并鉴定出了15种稳定存在于翘芪复方中药汤剂中的微小核糖核酸。其中,QQ_159被证明对病毒性流行性感冒及新型冠状病毒感染导致的肺炎存在一定的抑制效果和治疗作用。本发明不仅获得了中药抗病毒的天然有效成分,也将为临床治疗流感或新冠肺炎提供可能的核酸药物。
附图说明
图1为实施例2中real-time PCR检测QQ_159对乙型流感病毒载量的抑制效果;
图2为实施例3中QQ_159对感染H5N1禽流感病毒的小鼠体重的影响;
图3为实施例3中QQ_159对感染H5N1禽流感病毒的小鼠存活率的影响;
图4为实施例3中HE染色检测QQ_159对感染H5N1禽流感病毒的小鼠肺部炎症的抑制效果;
图5为实施例3中real-time PCR检测QQ_159对感染H5N1禽流感病毒第3天(A)和第5天(B)的小鼠肺部病毒载量的抑制效果;
图6为实施例4中HE染色检测QQ_159对感染SARS-CoV-2病毒的小鼠肺部炎症的抑制效果。
具体实施方式
为使本发明要解决的技术问题、技术方案和优点更加清楚,下面将结合附图与具体实施例进行详细描述。
实施例1翘芪复方中药汤剂微小核糖核酸的提取
(1)300mL翘芪复方中药(金银花、连翘、黄芩、青蒿、生黄芪、炒白术、藿香、防风、麦冬、甘草)汤剂分装于50mL除酶离心管中,2000rpm离心去除杂质;按每管10mL吸取上清置于冰上,按药汤体积3倍比例加入TRIzol ls 30mL,用力震荡均匀后,室温静置10min,然后加入6mL氯仿,用力震荡均匀,静置10min。
(2)离心10000g,4℃,10min,收集上清。
(3)加入等体积的异丙醇沉淀1h(-20℃),然后离心12000g,15min。
(4)小心弃上清,加入5mL的75%的乙醇洗沉淀,4℃,12000g离心5min。
(5)离心后,小心弃去乙醇,留沉淀,待沉淀干燥后加200μL 65℃DEPC水溶解,测定RNA浓度。
(6)用商用miRNA isolation kit纯化miRNA(每个柱子过100μg RNA),每管用60μLDEPC水溶解。
(7)测定miRNA浓度,冷冻干燥8h后,-80℃保存。
(8)采用BGISEQ-500技术进行微小核糖核酸测序,测序结果如下表1所示。
表1翘芪复方中药汤剂微小核糖核酸列表
实施例2测定QQ_159对马丁达比狗肾(MDCK)细胞中乙型流感病毒载量的影响
(1)在24孔培养板内培养MDCK细胞。
(2)分别将10nM、50nM或100nM QQ_159a通过商用转染试剂riboFECTTM CP转染入MDCK细胞,同时将相同浓度的无义序列转染至MDCK细胞作为对照组。
(3)使用乙型Victoria系流感病毒感染上述细胞。
(4)感染病毒24h后,收集上清离心合并细胞,提取RNA,通过real-time PCR检测病毒载量。
结果如图1所示,和对照组相比,100nM QQ_159能显著抑制MDCK细胞中乙型Victoria系流感病毒的病毒载量。
实施例3测定QQ_159对小鼠感染H5N1亚型禽流感病毒的治疗效果
(1)6周龄的BALB/C母鼠感染H5N1亚型禽病毒后2h,腹腔注射药物。动物分组及药物用量见下表2。
表2 QQ_159抗H5N1禽流感动物实验分组及药物处理情况
表2中:混合RNA为从翘芪复方中药汤剂汇总提取的混合RNA。
(2)连续给药5天,每天观察记录体重变化(若体重下降超过30%,安乐处死,视作死亡)。
(3)分别于攻毒后第3、第5天取肺组织,HE染色检测肺组织炎症情况。
(4)real-time PCR检测肺组织病毒载量。
(5)饲养动物至第10天,观察存活率。
结果:在体重变化方面,如图2所示,中浓度QQ_159(120pmol/只/天,M-QQ_159)、高浓度QQ_159(360pmol/只/天,H-QQ_159)以及混合RNA组在攻毒后的第7天(图2中显示D8)体重变化进入平台期,但感染对照组仍有下降的趋势;高浓度QQ_159组的体重变化率略高于混合RNA组和中浓度QQ_159。在存活率方面,如图3所示,中浓度QQ_159组和混合RNA组的存活率达70%,高浓度QQ_159组的存活率为50%,而感染组仅有30%的存活率。如图4所示,HE结果显示和感染对照组相比,混合RNA组和中浓度QQ_159小鼠肺部炎症明显减轻,且中浓度QQ_159抑制效果更佳。如图5A所示,感染后第3天,中浓度QQ_159组、高浓度QQ_159组和混合RNA组均能有效抑制病毒的复制;如图5B所示,在感染后的第5天,中浓度QQ_159抑制病毒复制效果明显减弱,而高浓度QQ_159组和混合RNA组对抑制病毒复制仍有较好效果。
该实验表明,人工合成的QQ_159及从翘芪复方中药汤剂汇总提取的混合RNA对H5N1禽流感病毒存在一定的治疗作用,表现为体重下降延缓、死亡率的降低以及肺部炎症的减轻。
实施例4研究QQ_159抑制SARS-CoV-2病毒引起的肺炎的效果
(1)SARS-CoV-2以105TCID50/mL滴鼻感染6~8周龄hACE2转基因小鼠。
(2)腹腔注射(ip)给药,给药5天。第一天染毒2h后给药。实验分组和用药剂量见下表3。
表3 hACE2转基因小鼠SARS-CoV-2感染实验
(3)在0、1、2、3、4、5天监测体重和症状。
(4)感染后第5天处死小鼠,收集肺组织。
(5)HE染色检测肺组织病理。
结果如图6所示,120pmol/只/天注射QQ_159对感染SARS-CoV-2的hACE2转基因小鼠肺组织炎症具有一定的抑制效果,表明QQ_159对SARS-CoV-2感染引起的小鼠肺炎具有一定抑制效果。
以上所述仅是本发明的优选实施方式,应当指出,对于本领域技术人员来说,在不脱离本发明所述原理的前提下,还可以作出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
序列表
<110> 南通大学
<120> 一种翘芪复方中药汤剂来源的微小核糖核酸及其制备方法和应用
<160> 15
<170> SIPOSequenceListing 1.0
<210> 1
<211> 28
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 1
ccagcacuaa ugcaccggau cccaucag 28
<210> 2
<211> 25
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 2
ugggaagucc ucguguugua ccccu 25
<210> 3
<211> 28
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 3
gccuucgaug ucggcucuuc cuaucauu 28
<210> 4
<211> 29
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 4
ucguccagcg guuaggauau cuggcuuuc 29
<210> 5
<211> 24
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 5
gcggaucuug gugguaguag caaa 24
<210> 6
<211> 30
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 6
cucgggaaaa ggauuggcuc ugagggcugg 30
<210> 7
<211> 25
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 7
acacaugcaa gucgaacguu guuuu 25
<210> 8
<211> 28
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 8
gugugcaccg gucgucucgu cccuucug 28
<210> 9
<211> 24
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 9
ucuggguggu guaguugguu auca 24
<210> 10
<211> 20
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 10
cguuucacgu cggguucacc 20
<210> 11
<211> 23
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 11
gugguuagga caucgucuuu uca 23
<210> 12
<211> 26
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 12
gucuguaguu cgauccugca uggggg 26
<210> 13
<211> 20
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 13
uggcgcuaga aggagggccu 20
<210> 14
<211> 21
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 14
uuuggauuga agggagcucu a 21
<210> 15
<211> 20
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 15
cuuggauuga agggagcucu 20
Claims (2)
1.一种翘芪复方中药汤剂来源的微小核糖核酸在制备治疗病毒性流行性感冒的药物中的应用,其特征在于,所述微小核糖核酸为QQ_159,核苷酸序列如SEQ ID NO.14所示;所述流行性感冒为乙型victoria流行性感冒或H5N1禽流感。
2.一种翘芪复方中药汤剂来源的微小核糖核酸在制备治疗SARS-CoV-2病毒引起的病毒性肺炎的药物中的应用,其特征在于,所述微小核糖核酸为QQ_159,核苷酸序列如SEQ IDNO.14所示。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210424718.8A CN114606236B (zh) | 2022-04-21 | 2022-04-21 | 一种翘芪复方中药汤剂来源的微小核糖核酸及其制备方法和应用 |
EP22926310.8A EP4296356A1 (en) | 2022-04-21 | 2022-05-25 | Forsythia suspensa and radix astragali compound traditional chinese medicine decoction-derived micro ribonucleic acid, and preparation method therefor and use thereof |
PCT/CN2022/094829 WO2023201836A1 (zh) | 2022-04-21 | 2022-05-25 | 一种翘芪复方中药汤剂来源的微小核糖核酸及其制备方法和应用 |
JP2023555359A JP2024517548A (ja) | 2022-04-21 | 2022-05-25 | レンギョウ・オウギ復方漢方薬煎剤由来のマイクロリボ核酸、その製造方法、及び使用 |
KR1020237031655A KR20230151524A (ko) | 2022-04-21 | 2022-05-25 | 전통 한약 달임 연교-황기 추출물에서 유래한 마이크로 rna 및 이의 제조방법 및 용도 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210424718.8A CN114606236B (zh) | 2022-04-21 | 2022-04-21 | 一种翘芪复方中药汤剂来源的微小核糖核酸及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114606236A CN114606236A (zh) | 2022-06-10 |
CN114606236B true CN114606236B (zh) | 2024-01-05 |
Family
ID=81869635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210424718.8A Active CN114606236B (zh) | 2022-04-21 | 2022-04-21 | 一种翘芪复方中药汤剂来源的微小核糖核酸及其制备方法和应用 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4296356A1 (zh) |
JP (1) | JP2024517548A (zh) |
KR (1) | KR20230151524A (zh) |
CN (1) | CN114606236B (zh) |
WO (1) | WO2023201836A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104640987A (zh) * | 2012-08-15 | 2015-05-20 | 北京命码生科科技有限公司 | 植物微小核糖核酸的提取、制备及其应用 |
CN105177002A (zh) * | 2015-09-15 | 2015-12-23 | 中国科学院遗传与发育生物学研究所 | 与大麦抗白粉病相关的miR159a及其应用 |
CN111249299A (zh) * | 2020-03-31 | 2020-06-09 | 南京财经大学 | 大豆rna提取物在制备预防及治疗肠炎的药物中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050144669A1 (en) * | 2003-07-01 | 2005-06-30 | Whitehead Institute For Biomedical Research | MicroRNAs in plants |
JP2008522585A (ja) * | 2004-10-12 | 2008-07-03 | ザ ロックフェラー ユニバーシティー | マイクロrna |
CN111249390A (zh) * | 2020-03-12 | 2020-06-09 | 尧舜泽生物医药(南京)有限公司 | 一种翘芪复方制剂及其制备方法和用途 |
-
2022
- 2022-04-21 CN CN202210424718.8A patent/CN114606236B/zh active Active
- 2022-05-25 JP JP2023555359A patent/JP2024517548A/ja active Pending
- 2022-05-25 KR KR1020237031655A patent/KR20230151524A/ko unknown
- 2022-05-25 WO PCT/CN2022/094829 patent/WO2023201836A1/zh active Application Filing
- 2022-05-25 EP EP22926310.8A patent/EP4296356A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104640987A (zh) * | 2012-08-15 | 2015-05-20 | 北京命码生科科技有限公司 | 植物微小核糖核酸的提取、制备及其应用 |
CN105177002A (zh) * | 2015-09-15 | 2015-12-23 | 中国科学院遗传与发育生物学研究所 | 与大麦抗白粉病相关的miR159a及其应用 |
CN111249299A (zh) * | 2020-03-31 | 2020-06-09 | 南京财经大学 | 大豆rna提取物在制备预防及治疗肠炎的药物中的应用 |
Non-Patent Citations (2)
Title |
---|
油菜miR156基因家族及其靶基因生物信息学分析及鉴定;李晓康等;《中国油料作物学报》;第40卷(第2期);第163-173页 * |
黄芪饮片 miRNA 谱及热力学的稳定性研究;沈朝斌等;《中草药》;第46卷(第20期);摘要 * |
Also Published As
Publication number | Publication date |
---|---|
CN114606236A (zh) | 2022-06-10 |
JP2024517548A (ja) | 2024-04-23 |
KR20230151524A (ko) | 2023-11-01 |
EP4296356A1 (en) | 2023-12-27 |
WO2023201836A1 (zh) | 2023-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9752148B2 (en) | Extraction, preparation, and application of plant micro-ribonucleic acid | |
Pang et al. | Antiviral effects of aqueous extract from Spatholobus suberectus Dunn. against coxsackievirus B3 in mice | |
WO2014026333A1 (zh) | 植物微小核糖核酸的提取、制备及其应用 | |
CN107468683B (zh) | 土木香内酯及其衍生物在制备预防和治疗脂肪肝损伤药物中的用途 | |
CN114606236B (zh) | 一种翘芪复方中药汤剂来源的微小核糖核酸及其制备方法和应用 | |
CN111867610B (zh) | 用于预防或治疗呼吸系统疾病的生药组合物 | |
JP2005502602A (ja) | ウイルス感染の治療用の医薬組成物 | |
CN114949024A (zh) | 小蓟总黄酮、制备方法及其在制备预防或治疗高尿酸血症药物中的应用 | |
CN110302209B (zh) | 一种miR-451a反义链抑制剂及其应用 | |
CN106822152B (zh) | 一种药物组合物及其应用 | |
CN113082080B (zh) | 八角属植物或其提取物在制备抗动物病毒药物中的用途 | |
CN116350673A (zh) | 一种抗流感、呼吸道合胞病毒的甘草总皂苷颗粒的制备方法和应用 | |
CN114681540B (zh) | 中药组合物在制备抗冠状病毒药物上的应用 | |
CN114796189B (zh) | 一种用于呼吸道病原体感染的治疗和预防的药物组合物及应用 | |
CN111773258B (zh) | 一种抗流感病毒的蒙药、药物组合物及其制备方法和应用 | |
CN109078051B (zh) | 一种药物组合物在制备抗病毒药物中的应用 | |
CN113633652B (zh) | 甘草苷在制备治疗或预防肠道病毒71型感染药物中的应用 | |
CN115227738B (zh) | 紫苏叶提取物在制备抗病毒药物中的用途 | |
CN114209728B (zh) | 具有调控表观遗传表达平衡抗肝癌作用的野菊花活性部位及其制备方法和应用 | |
CN102940686B (zh) | 川楝子提取物在制备抗病毒药物中的应用及其提取方法 | |
CN110859900B (zh) | 六灵解毒丸在制备用于防治感冒疾病的药物中的应用 | |
CN107296827B (zh) | 一种抗甲型h1n1流感药物组合物及其应用 | |
CN116473979A (zh) | 甲基巴多索隆在制备抑制呼吸道合胞病毒感染药物中的应用 | |
CN117695326A (zh) | 决明子在制备抗呼吸道合胞病毒的药物中的应用 | |
CN114869985A (zh) | 一种中药组合物在制备治疗冠状病毒的药物上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |